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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this review is to determine the effect of SBPM in adults with hypertension on blood pressure control as compared to
OBPM or usual care.
B A C K G R O U N D
Hypertension has been well recognised for many years as one of
the most important modifiable risk factors in the prevention of
stroke and cardiovascular disease (MacMahon 1990). Globally the
public health burden of the disease continues to be a significant
problem with an increasingly aging population (Kearney 2005).
However, despite this, blood pressure control among hypertensive
patients remains poor with only a minority of people treated to
satisfactory levels (Wolf-Maier 2004).
Due to the low cost and broad availability of validated elec-
tronic BP devices (O’Brien 2010), self blood pressure monitor-
ing (SBPM) at home by patients is increasingly common and is
regarded as a more reliable and reproducible representation of
blood pressure control due to minimisation of the white coat ef-
fect (Stergiou 2002). It has been recommended for the evaluation
of hypertension (NICE 2011) as well as a tool for increasing the
likelihood of therapeutic intensification in response to above tar-
get blood pressure readings (Agarwal 2011).
SBPM empowers patients; it is cost effective (McManus 2005),
well tolerated and has been shown to be a better predictor of end
organ damage than traditional office blood pressure monitoring
(OBPM) (Bobrie 2004).
Why it is important to do this review
Themost recent Cochrane review on interventions to improve hy-
pertension management (Glynn 2010) proved too large for timely
updates. It classified 72 trials of interventions, based on searches
from 2008, into six categories: self monitoring, patient education,
health professional education, health professional led care (nurse
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and/or pharmacist), appointment reminder systems and organisa-
tional interventions. The review concluded that self-monitoring
and appointment reminders may be useful adjuncts to antihyper-
tensive drug therapy implemented by means of a vigorous stepped
care approach, but required further evaluation.
Since then there has been an increasing body of literature which
pertains to the beneficial effect of home blood pressure monitoring
on blood pressure control in hypertensive patients (Bray 2010 - 25
trials) (Agarwal 2011 - 37 trials) (Uhlig 2012 - 49 trials). The aim
of this review is to provide an up-to-date assessment on the effec-
tiveness of self-monitoring in the management of hypertension. A
previous version of this review (Bray 2010) requires updating due
to new studies in the last two years relating to the effects of home
blood pressure monitoring.
O B J E C T I V E S
The objective of this review is to determine the effect of SBPM in
adults with hypertension on blood pressure control as compared
to OBPM or usual care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) are eligible if the interven-
tion group includes home or self blood pressure measurement, if
the usual care or control group does not include home/self-moni-
toring and if a blood pressure outcome measure is available which
has been taken independently of the self measurement. These are
usually either systolic or diastolic office BP readings or mean day-
time ambulatory BP readings. Trials will be considered that in-
clude self-monitoring as a sole intervention or as an adjunct to
other interventions (e.g. education, nurse/ pharmacist support,
telemonitoring, etc).
Types of participants
The participants of interest are adult patients (18 years or over)
with a diagnosis of primary hypertension (either treated or not
treated with antihypertensive medications) assessed in a primary
care, outpatient or community setting.
Types of interventions
The intervention of interest is home or self monitoring of blood
pressure in patients with hypertension.
Types of outcome measures
Primary outcomes
Studies will be included if they report:
1. Change in mean office systolic blood pressure (SBP) and/or
mean office diastolic blood pressure (DBP)
2. Change in mean systolic and diastolic ambulatory blood
pressure (ABP)
3. The proportion of participants achieving target BP in each
group (control as defined by each randomised trial’s investigators)
Secondary outcomes
Additional secondary outcomes that will be looked at are:
• ’Therapeutic intensification’ - defined as the addition of
another antihypertensive agent, increasing dosage of medication
or both in response to above target blood pressure readings (this
outcome will be assessed by subgroup analysis of treated and
untreated patients)
• Adverse events in the self monitoring and control groups
including any evidence of mortality or cardiovascular morbidity
• Adherence to intervention (drop out rate)
• Adherence to medication (compliance rate)
• Health related quality of life data related to self-monitoring
of blood pressure
• Other surrogate markers such as LVH (left ventricular
hypertrophy) or LV mass
Search methods for identification of studies
Electronic searches
The following electronic databases will be searched:
The Hypertension Group specialised register (1946 to October
2012), the Cochrane Central Register of Controlled Trials (CEN-
TRAL) 2012 Issue 10, the Hypertension Group specialised regis-
ter (1946 toOctober 2012), MEDLINE (2009 toOctober 2012),
and EMBASE (2009 to October 2012). The MEDLINE search
strategy (Appendix 1) will be translated into the other databases
using the appropriate subject headings and syntax.
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Searching other resources
Information from grey literature sources, such as internal reports
and conference proceedings will be sought. The references of all
retrieved archiveswill be screened and experts in the field contacted
for potentially relevant trials or unpublished material of systematic
reviews and meta-analyses. In addition we will maintain dialogue
and share results with the authors of collaborating teams from the
split of the existing review.
Data collection and analysis
Two separate authors (NQ and EB) will independently assess the
list of citations and abstracts generated from the searches for eli-
gibility.
Selection of studies
Studies that are clearly irrelevant will be excluded on the basis of
their titles if possible. The remaining abstracts will be reviewed
and identified as potentially relevant, not relevant or uncertain.
Potentially relevant and uncertain articles will be retrieved in full
when a final decision will be made on eligibility by two indepen-
dent reviewers. Disagreements on classification will be discussed
and arbitrated by a third author (RJM). No additional method-
ological quality criteria including study size or language of publi-
cation will be applied.
Data extraction and management
Data extraction will occur independently by two authors (NQ and
EB) regarding study design, methods, clinicians and patients, in-
terventions, outcomes and potential sources of bias using a struc-
tured data collection pro forma. Where studies report outcomes at
more than one time point (e.g. 6 and 12 months), data concerning
the longest follow up will be extracted. Again any differences in
the interpretation of the data will be resolved by discussion and
arbitration with a third author (RJM). Where data are found to be
missing, or further enquiries needed, the original authors of the
studies will be contacted.
Assessment of risk of bias in included studies
For assessment of study quality and reporting bias, we will use the
Cochrane Collaboration ’Risk of Bias’ (ROB) assessment tool to
record and describe the methods used in randomisation sequence
generation, allocation concealment, blinding of participants for
each main outcome and class of outcomes. We will also use the
ROB tool to assess attrition bias by looking at the completeness
of outcome data for each main outcome including the number
of exclusions in each intervention group (compared to the total
participants randomised) and whether these were reported and
included in the analysis. Reporting bias due to selective outcome
reporting by the review authors will be examined as well as other
sources of bias. This process of assessing bias will be carried out
independently by two separate authors (NQ and EB).
Measures of treatment effect
Weightedmeandifferences (WMD)will be calculated for the over-
all change in systolic and diastolic blood pressure (both for office
and ABPM) between intervention and control. Depending upon
the measurement indices used in individual studies, Relative Risk
(RR) or Odds Ratio (OR) will be the preferred choice when re-
porting other primary and secondary outcomes. Risk Difference
(RD) may also be a relevant measure of treatment effect for some
of the outcomes.
Unit of analysis issues
Care will be taken to avoid problematic unit of analysis issues
if the same group of participants are included twice in the same
meta-analysis. Where studies including more than one interven-
tion group with a single comparator arm are used, both inter-
vention groups will be included and the number of patients split
across the interventions arms.
Dealing with missing data
Any potential missing data will be discussed by the authors of
this review and if necessary clarified by corresponding with the
relevant study authors. All participants not receiving the assigned
intervention according to the protocol as well as those dropping
out or lost to follow up, will be included in the analysis on an
intention to treat basis. This will be performed, with sensitivity
analysis, by either available case analysis or imputation (see sec-
tion 16.2.3 of Cochrane Handbook). In looking at the primary
outcomes, where the standard deviation (SD) of the change in BP
is not reported, this will be estimated using elementary theory of
differences of correlated variables from the SD at baseline and final
measurement (as per Bray 2010, p2, appendix 1).
Assessment of heterogeneity
Clinical heterogeneity will be assessed qualitatively by comparing
the study characteristics of included trials and quantified using
the chi-square test of systematic variation and the I2 statistic. Het-
erogeneity will be explored with sensitivity analysis by excluding
single outlying results or restricting analysis to studies at low risk
of bias. This will be further analysed using meta-regression with
backward elimination to assess the associations between the treat-
ment effect and the study characteristics (see below). Pooled data
will only be reported where heterogeneity is not statistically sig-
nificant (P>0.05). In addition heteroscedasticity between studies
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will be assessed and possible contributing factors will be investi-
gated. This will be done using specialist statistical software such
as STATA or SPSS.
Assessment of reporting biases
Reporting bias will be considered where studies do not report
absolute BP measures at follow up in favour of indirect measures
(e.g. change from baseline, achievement of target). Publication
bias will be assessed by producing funnel plots of effect size and
of sample size against WMD to provide a visual review of any
potential bias
Data synthesis
Pooling and analysis of data will be carried out with RevMan
5. Separate analyses will be conducted for each intervention and
outcome measure compared to usual care. Intervention effects will
be calculated as relative risks with 95% confidence intervals for
dichotomous data. For continuous data, we will calculate mean
differences and WMDs with 95% confidence intervals using a
conservative fixed-effects meta-analysis model in the absence of
significant heterogeneity (p>0.05 or I2<50%), or a random-effects
model if heterogeneity is present.
In addition, the quality of the body of the evidence will be analysed
according to the GRADE system as set out in chapter 12.2.1 of
the Cochrane Handbook. This will take into account themethod-
ological quality, directness of evidence, heterogeneity, precision of
effect estimates and risk of publication bias. See below for example
of Summary of Findings table.
Subgroup analysis and investigation of heterogeneity
The primary analysis will include all trials. Meta-regression will
be used to investigate the effects of different study characteris-
tics on treatment effects. Planned subgroups will include terms
for age (continuous variable), sex of participants (male or female),
length of follow up (continuous variable), number of treated or
untreated patients (all treated, all untreated or mix of treated and
untreated), mean baseline diastolic blood pressure (categorised to
nearest 5mmHg) and use of additional co-interventions (where
these are part of the intervention in addition to self-monitoring).
The variables that will be analysed continuously will not be cat-
egorised in advance in order to increase the power of the meta-
regression and more reliably allow determination of the incremen-
tal effects of these variables. Different studies include different age
groups of patients and length of follow-up; hence, using arbitrary
cut-off points may introduce an added source of bias. In case of
non linear relationships between these variables and outcomes not
detected by meta-regression as well as to further explore relation-
ships where detected, these prespecified variables will be further
investigated in an exploratory analysis examining the individual
categories (quintiles in the case of continuous variables), in order
to elucidate the nature of this relationship.
Sensitivity analysis
Sensitivity analysis will be performed to assess the impact of each
study on the overall outcome with recalculation of both WMDs
and meta-regression with the removal of each study one at a time
from the analysis.
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A P P E N D I C E S
Appendix 1. Medline Search Strategy
Database: Ovid MEDLINE(R) 1946 to Present with Daily Update
--------------------------------------------------------------------------------
1 blood pressure monitoring, ambulatory/
2 ((blood pressure or bp) adj3 (24h or 24hr? or 24-h or 24-hr? or 24 hour? or ambulatory or determin$ or measur$ or monitoring or
monitor$ or self-measur$ or self-monitor$)).tw.
3 or/1-2
4 (home or self$).tw.
5 (telemedicine or tele-medicine or telemonitor$ or tele-monitor$).mp.
6 or/4-5
7 randomized controlled trial.pt.
8 controlled clinical trial.pt.
9 randomized.ab.
10 placebo.ab.
11 drug therapy.fs.
12 randomly.ab.
13 trial.ab.
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14 groups.ab.
15 or/7-14
16 animals/ not (humans/ and animals/)
17 15 not 16
18 3 and 6 and 17
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